Weight Loss

How Much Weight Can You Lose on GLP-1 Medications? Realistic Expectations

GLP-1 Companion · 8 min read

GLP-1 receptor agonists have transformed the landscape of medical weight management. Medications like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) consistently produce greater weight loss than any previous pharmaceutical option. But headlines about dramatic results can create unrealistic expectations. Understanding what the clinical data actually shows — and what influences individual outcomes — is essential for setting achievable goals.

Clinical Trial Results by Medication

Large-scale clinical trials provide the most reliable data on average weight loss with GLP-1 medications. Keep in mind that trial participants also received lifestyle counseling, which contributes to results.

Semaglutide 2.4mg (Wegovy)

The STEP 1 trial enrolled over 1,900 adults with obesity or overweight with at least one weight-related comorbidity. After 68 weeks, participants on semaglutide 2.4mg lost an average of 14.9% of their body weight, compared to 2.4% in the placebo group. About one-third of participants lost 20% or more of their body weight.

Semaglutide 1mg (Ozempic)

Ozempic is approved for type 2 diabetes at a maximum dose of 2mg, not specifically for weight loss. In the SUSTAIN trials, patients on semaglutide 1mg lost an average of 4.5–6.5kg (roughly 5–7% of body weight) over 30–56 weeks. The lower dose compared to Wegovy accounts for the more modest weight loss.

Tirzepatide (Mounjaro / Zepbound)

The SURMOUNT-1 trial studied tirzepatide in over 2,500 adults with obesity. At the highest dose (15mg), participants lost an average of 22.5% of their body weight over 72 weeks. Even at the lowest therapeutic dose (5mg), average weight loss was 16%. These results represent the largest average weight loss seen in any obesity medication trial to date.

Liraglutide (Saxenda)

Saxenda, an earlier GLP-1 medication requiring daily injections, produced average weight loss of about 8% of body weight over 56 weeks in the SCALE trials. While meaningful, this is less than the newer weekly injectables.

What "Average" Really Means

Clinical trial averages can be misleading because they mask significant individual variation. In the STEP 1 trial, while the average was about 15%, individual results ranged from minimal weight loss (under 5%) to exceptional results (over 30%). Roughly 10–15% of participants in most GLP-1 trials are classified as "non-responders," losing less than 5% of their body weight.

Factors That Influence Your Results

Several variables determine where you fall on the spectrum of weight loss outcomes.

• Starting weight — People with higher starting BMI often lose more total weight but may lose a similar percentage of body weight compared to those starting at a lower weight.
• Medication and dose — Higher doses generally produce greater weight loss. Tirzepatide has shown larger effects than semaglutide in head-to-head comparisons.
• Diet and exercise — GLP-1 medications are most effective when combined with a reduced-calorie diet and regular physical activity. Medications reduce appetite, but food choices and movement still matter.
• Metabolic factors — Insulin resistance, thyroid function, hormonal status, and other metabolic conditions can affect the rate and extent of weight loss.
• Genetics — Emerging research suggests genetic variations in GLP-1 receptor sensitivity may partly explain why some individuals respond better than others.
• Adherence — Missed doses, inconsistent injection timing, and early discontinuation all reduce effectiveness.
• Sleep and stress — Chronic sleep deprivation and high cortisol levels can blunt weight loss regardless of medication use.
• Other medications — Some medications (certain antidepressants, corticosteroids, insulin) can promote weight gain and partially offset GLP-1 effects.

The Weight Loss Plateau

Most patients on GLP-1 medications experience a plateau after 12–18 months, where weight loss slows significantly or stops. This is a normal physiological response, not a sign that the medication has stopped working. As you lose weight, your body requires fewer calories, and metabolic adaptation reduces energy expenditure. The medication continues to work by helping maintain the weight you have already lost.

A plateau is not a failure — it is your body reaching a new equilibrium. The medication is still providing benefit by preventing weight regain.

Maintaining Weight Loss Long-Term

One of the most important findings from GLP-1 research is what happens when patients stop the medication. The STEP 1 extension trial showed that participants regained approximately two-thirds of lost weight within one year of discontinuing semaglutide. This underscores that GLP-1 medications treat an ongoing condition rather than providing a temporary fix.

• Most current evidence supports long-term or indefinite use for sustained weight management.
• Building healthy habits (regular exercise, balanced nutrition, adequate protein) during treatment helps preserve results.
• Resistance training is critical for maintaining lean muscle mass, which supports a higher metabolic rate.
• Regular follow-up with your healthcare provider allows for dose adjustments and ongoing support.

Setting Realistic Goals

Rather than targeting a specific number on the scale, focus on health improvements. A weight loss of 5–10% of body weight is associated with meaningful reductions in blood pressure, blood sugar, cholesterol, and joint pain. Any amount of sustained weight loss with improved metabolic markers is a clinical success, even if it falls below the trial averages.

Key Takeaways

1. Average weight loss ranges from about 8% (Saxenda) to 22.5% (Mounjaro 15mg) of body weight over 12–18 months.
2. Individual results vary significantly — some people lose much more or less than average.
3. Diet, exercise, sleep, and adherence all influence outcomes alongside the medication itself.
4. Weight loss typically plateaus after 12–18 months, which is normal.
5. Long-term use is generally needed to maintain weight loss, as discontinuation often leads to regain.
6. Focus on overall health improvements, not just the number on the scale.

Sources

• Wilding et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. NEJM.
• Jastreboff et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. NEJM.